BridgeBio's Oral Dwarfism Drug Infigratinib Achieves Best-in-Class Results in Pivotal Achondroplasia Trial
核心洞察
BridgeBio's oral drug infigratinib demonstrated superior growth acceleration in children with achondroplasia (搜索), achieving 1.74-2.1 cm per year improvement over placebo in a pivotal trial of over 100 patients.
The drug showed best-in-indication efficacy compared to existing injectable treatments, with BioMarin's Voxzogo showing 1.57 cm per year and Ascendis' therapy showing 1.49-1.78 cm per year in their respective trials.
Infigratinib was well-tolerated with no serious adverse events or treatment discontinuations due to side effects, positioning it as a convenient oral alternative to current daily injection therapies.
BridgeBio Pharma's experimental oral drug infigratinib has achieved breakthrough results in a pivotal clinical trial for achondroplasia (搜索), the most common genetic cause of dwarfism (搜索), demonstrating superior efficacy compared to existing treatments and setting the stage for regulatory approval later this year.
The Phase 3 trial enrolled approximately 110 children with achondroplasia (搜索) over a one-year treatment period, comparing infigratinib to placebo. Children receiving the oral medication experienced accelerated growth of 2.1 centimeters per year compared to placebo, with an adjusted treatment difference of 1.74 centimeters per year. Both measurements achieved statistical significance and represent what BridgeBio characterized as record-setting results for randomized achondroplasia studies.
Superior Efficacy Profile Emerges
The infigratinib results notably outperformed existing approved and investigational therapies. BioMarin Pharmaceutical's Voxzogo, currently the only FDA-approved treatment for achondroplasia (搜索), demonstrated an annualized growth velocity of 1.57 cm per year compared to placebo in its pivotal trial. Ascendis Pharma's investigational once-weekly injection showed a treatment difference of 1.49 cm per year overall, rising to 1.78 cm per year in children aged 5 to 11.
"These results represent meaningful progress for those who have been waiting for a better approach," said Daniela Rogoff, chief medical officer of BridgeBio's skeletal dysplasia unit, highlighting significant demand among achondroplasia (搜索) patients for therapeutic options that are effective, practical, and less invasive than current treatments.
Favorable Safety and Tolerability Profile
The trial demonstrated a clean safety profile, with no serious adverse events attributed to infigratinib and no patient discontinuations due to side effects. BridgeBio reported three cases of patients developing abnormally high phosphate levels in their blood, but all instances were mild, transient, asymptomatic, and did not require dose modifications or treatment cessation.
Mechanism and Market Positioning
Infigratinib works by directly targeting and blocking FGFR3 (搜索), a protein that becomes overactive in multiple types of dwarfism (搜索). This protein inhibits bone growth by preventing cartilage cells from multiplying, maturing, and converting into bone tissue. The oral administration route offers a significant convenience advantage over current injectable therapies.
Achondroplasia (搜索) affects an estimated one in every 15,000 to 40,000 newborns. BioMarin's Voxzogo, administered as a daily injection, generated $654 million in revenue from January through September of the previous year, representing more than a quarter of the company's total revenue.
Regulatory Timeline and Market Impact
Based on the positive results, BridgeBio plans to meet with regulatory authorities to discuss marketing application submissions in the second half of 2026. The company also intends to accelerate infigratinib's development in hypochondroplasia (搜索), another form of dwarfism (搜索) where the drug is currently undergoing mid-stage testing.
Market analysts have responded positively to the results. Leerink Partners analyst Mani Foroohar had previously estimated that demonstrating above 2 cm per year improvement in height growth rate with a clean safety profile could add approximately $2 billion to BridgeBio's valuation. TD Cowen analyst Tyler Van Buren characterized the results as "best-in-indication," noting that physicians indicated even comparable efficacy to injectable drugs would support half of all patients switching to an oral option.
BridgeBio's stock price surged more than 15% in pre-market trading following the announcement, adding to the company's 140% share price increase over the past year. The biotechnology company's market capitalization exceeded $14 billion as of the announcement.
Michael Hughes, chair of the biotech industry liaison committee at patient advocacy organization Little People of America (搜索), called the announcement "another milestone in achondroplasia (搜索) research," underscoring the clinical significance for the patient community.